NCT06839105View on ClinicalTrials.gov

A Clinical Study to Evaluate the Safety and Tolerability of AWT020 in Patients With Advanced Malignancies

PHASE1RecruitingINTERVENTIONAL
Enrollment

214

Participants

Timeline

Start Date

February 21, 2025

Primary Completion Date

April 30, 2028

Study Completion Date

April 30, 2028

Conditions
Non-Small Cell Lung Cancer, Colorectal Cancer, Renal Cell Carcinoma, Melanoma and Other Solid Tumor
Interventions
DRUG

Taxol

135\~175 mg/m2, Q3W

DRUG

Cisplatin or Carboplatin

Cisplatin(75 mg/m2, Q3W) or Carboplatin (AUC=5\~6, Q3W)

DRUG

Pemetrexed

500 mg/m2, Q3W

DRUG

Oxaliplatin

130 mg/m2, Q3W

DRUG

Capecitabine

1000 mg/m2, BID, day1-14, oral, q3w

DRUG

Bevacizumab

7.5 mg/kg, Q3W

DRUG

Renvastinib

8mg or 20mg, QD

DRUG

AWT020

q3w or q2w, i.v.

Trial Locations (13)

110042

NOT_YET_RECRUITING

Liaoning Cancer Hospital & Institute, Shenyang

150081

NOT_YET_RECRUITING

Harbin Medical University Cancer Hospital, Harbin

200032

RECRUITING

Shanghai Chest Hospital, Shanghai

310022

NOT_YET_RECRUITING

Zhejiang Cancer Hospital, Hangzhou

330006

RECRUITING

First Affiliated Hospital of Nanchang University, Nanchang

350014

RECRUITING

Fujian Cancer Hospital, Fuzhou

400042

RECRUITING

The First Hospital of China Medical University, Shenyang

410000

RECRUITING

Hunan Cancer Hospital, Changsha

430079

RECRUITING

Hubei Cancer Hospital, Wuhan

471099

NOT_YET_RECRUITING

The First Affiliated Hospital of Henan University of Science & Technology, Luoyang

510060

NOT_YET_RECRUITING

Sun Yat-sen University Cancer Center, Guangzhou

650118

NOT_YET_RECRUITING

Yunnan Cancer Hospital, Kunming

Unknown

NOT_YET_RECRUITING

The First Hospital of Jilin University, Changchun

All Listed Sponsors
lead

Shanghai Junshi Bioscience Co., Ltd.

OTHER